Evidence map›Paper›PMID 26423376›Full record

Observational studyThe lancet. HIV2015

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Sara Lodi, Andrew Phillips, Roger Logan, Ashley Olson, Dominique Costagliola, Sophie Abgrall, Ard van Sighem, Peter Reiss, José M Miró, Elena Ferrer and 20 more

Open access · greenAbstract readComparative StudyObservational Study
In one paragraph

Observational study in The lancet. HIV, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. MULTIPLY ROBUST ESTIMATORS OF CAUSAL EFFECTS FOR SURVIVAL OUTCOMES.Scandinavian journal of statistics, theory and applications · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 19 institutions in 7 countries.

Sara LodiDepartment of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA. Electronic address: slodi@hsph.harvard.edu.
Andrew PhillipsUniversity College London, London, UK.
Roger LoganDepartment of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA.
Ashley OlsonMedical Research Council Clinical Trials Unit, University College London, London, UK.
Dominique CostagliolaSorbonne Universités, University Pierre et Marie Curie (UPMC), UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Sophie AbgrallSorbonne Universités, University Pierre et Marie Curie (UPMC), UMR S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Antoine Béclère, Service de Médecine Interne, Clamart, France.
Ard van SighemStichting HIV Monitoring, Amsterdam, Netherlands.
Peter ReissStichting HIV Monitoring, Amsterdam, Netherlands; Academic Medical Center, Department of Global Health and Division of Infectious Diseases, University of Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
José M MiróHospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Elena FerrerBellvitge University Hospital, L'Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain.
Amy JusticeYale University School of Medicine, New Haven, and VA Connecticut Healthcare System, West Haven, CT, USA.
Neel GandhiDepartments of Epidemiology, Global Health, and Medicine, Emory University, Atlanta, GA, USA.
Heiner C BucherBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.
Hansjakob FurrerDepartment of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland.
Santiago MorenoRamón y Cajal Hospital, Madrid, Spain; University of Alcalá de Henares, Madrid, Spain.
Susana MongeUniversity of Alcalá de Henares, Madrid, Spain.
Giota TouloumiUniversity of Athens Medical School, Athens, Greece.
Nikos PantazisUniversity of Athens Medical School, Athens, Greece.
Jonathan SterneBristol University, Bristol, UK.
Jessica G YoungDepartment of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA.
Laurence MeyerUniversité Paris Sud, UMR 1018, and AP-HP, Hôpital de Bicêtre, Service de Santé Publique, le Kremlin Bicêtre, France.
Rémonie SengUniversité Paris Sud, UMR 1018, and AP-HP, Hôpital de Bicêtre, Service de Santé Publique, le Kremlin Bicêtre, France.
Francois DabisINSERM U897, Centre Inserm Epidémiologie et Biostatistique, Université de Bordeaux, and Bordeaux University Hospital, Department of Internal Medicine, Bordeaux, France.
Marie-Anne VandehendeINSERM U897, Centre Inserm Epidémiologie et Biostatistique, Université de Bordeaux, and Bordeaux University Hospital, Department of Internal Medicine, Bordeaux, France.
Santiago Pérez-HoyosConsorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Vall d'Hebron Research Institute, Barcelona, Spain.
Inma JarrínConsorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
Sophie JoseUniversity College London, London, UK.
Caroline SabinUniversity College London, London, UK.
Miguel A HernánDepartment of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T H Chan School of Public Health, and Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston, MA, USA.
HIV-CAUSAL Collaboration
University College London · GBHarvard University · USInstituto de Salud Carlos III · ESNational and Kapodistrian University of Athens · GRStichting HIV Monitoring · NLUniversidad de Alcalá · ESUniversité de Bordeaux · FRAssistance Publique – Hôpitaux de Paris · FRBellvitge University Hospital · ESEmory University · USHarvard–MIT Division of Health Sciences and Technology · USInstitut Pierre Louis d‘Épidémiologie et de Santé Publique · FRSorbonne Université · FRUniversitat de Barcelona · ESUniversité Paris-Sud · FRUniversity Hospital of Basel · CHUniversity Hospital of Bern · CHUniversity of Bristol · GBYale University · US

Funding

Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI John Edward Pachankis · 2001 to 2026
$48.5M
Alcohol and Multisubstance Use in the Veterans Aging Cohort StudyU01AA020790 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$7.7M
Dynamic strategies for the clinical management of HIV diseaseR01AI102634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HERNAN, MIGUEL · 2013 to 2017
$2.6M
Mentorship in Patient-Oriented Research in Tuberculosis, HIV and Global HealthK24AI114444 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2014 to 2023
$1.8M
Medical Research Council MC_UU_12023/15Medical Research Council MR/J002380/1Medical Research Council MR/M004236/1NIAAA NIH HHS U01 AA020790NIAID NIH HHS R01 AI102634NIMH NIH HHS P30 MH062294
6 · The paper itself

Abstract

backgroundRecommendations have differed nationally and internationally with respect to the best time to start antiretroviral therapy (ART). We compared effectiveness of three strategies for initiation of ART in high-income countries for HIV-positive individuals who do not have AIDS: immediate initiation, initiation at a CD4 count less than 500 cells per μL, and initiation at a CD4 count less than 350 cells per μL.

methodsWe used data from the HIV-CAUSAL Collaboration of cohort studies in Europe and the USA. We included 55,826 individuals aged 18 years or older who were diagnosed with HIV-1 infection between January, 2000, and September, 2013, had not started ART, did not have AIDS, and had CD4 count and HIV-RNA viral load measurements within 6 months of HIV diagnosis. We estimated relative risks of death and of death or AIDS-defining illness, mean survival time, the proportion of individuals in need of ART, and the proportion of individuals with HIV-RNA viral load less than 50 copies per mL, as would have been recorded under each ART initiation strategy after 7 years of HIV diagnosis. We used the parametric g-formula to adjust for baseline and time-varying confounders.

findingsMedian CD4 count at diagnosis of HIV infection was 376 cells per μL (IQR 222-551). Compared with immediate initiation, the estimated relative risk of death was 1·02 (95% CI 1·01-1·02) when ART was started at a CD4 count less than 500 cells per μL, and 1·06 (1·04-1·08) with initiation at a CD4 count less than 350 cells per μL. Corresponding estimates for death or AIDS-defining illness were 1·06 (1·06-1·07) and 1·20 (1·17-1·23), respectively. Compared with immediate initiation, the mean survival time at 7 years with a strategy of initiation at a CD4 count less than 500 cells per μL was 2 days shorter (95% CI 1-2) and at a CD4 count less than 350 cells per μL was 5 days shorter (4-6). 7 years after diagnosis of HIV, 100%, 98·7% (95% CI 98·6-98·7), and 92·6% (92·2-92·9) of individuals would have been in need of ART with immediate initiation, initiation at a CD4 count less than 500 cells per μL, and initiation at a CD4 count less than 350 cells per μL, respectively. Corresponding proportions of individuals with HIV-RNA viral load less than 50 copies per mL at 7 years were 87·3% (87·3-88·6), 87·4% (87·4-88·6), and 83·8% (83·6-84·9).

interpretationThe benefits of immediate initiation of ART, such as prolonged survival and AIDS-free survival and increased virological suppression, were small in this high-income setting with relatively low CD4 count at HIV diagnosis. The estimated beneficial effect on AIDS is less than in recently reported randomised trials. Increasing rates of HIV testing might be as important as a policy of early initiation of ART.

fundingNational Institutes of Health.

Indexed as

Antiretroviral Therapy, Highly ActiveComparative Effectiveness ResearchAdultCD4 Lymphocyte CountCohort StudiesDeveloped CountriesEuropeFemaleHIV-1HIV InfectionsHumansMaleMass ScreeningMiddle AgedPolicySurvival Rate

Identifiers

PMID26423376
PMCPMC4643831
OpenAlexW1606030167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.